Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Gyre Therapeutics (GYRE) AI Stock Analysis

830 Followers
GYRE

Gyre Therapeutics

(NASDAQ:GYRE)

Select Model
Rating:55Neutral
Price Target:$4.50â–²(12.22% Upside)
Action:reiterated
Date:10/31/26

The score is held up by a strong, conservatively financed balance sheet and very high gross profitability, plus generally positive strategy-related corporate updates. It is weighed down by a return to losses with uneven cash conversion and a clearly bearish technical trend (price below all major moving averages with negative MACD).

Positive Factors
High Gross ProfitabilityA roughly 94% gross margin indicates strong economics on products already generating revenue and provides substantial room to fund operating activities. This supports reinvestment in the pipeline and offers a durable foundation for improving profitability if operating costs become better controlled.
Negative Factors
Return to Net LossesThe return to a material net loss after positive net income in 2024 and 2025 shows that revenue growth is not currently translating into durable bottom-line profitability. Continued losses could constrain internal funding capacity and increase dependence on successful future execution.

Gyre Therapeutics (GYRE) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%GYRE-49.37%SPY+10.42%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$470.79M
Dividend Yield
―
Average Volume (3M)
143.47K
Price to Earnings (P/E)
-14.4
Beta (1Y)
1.78
Revenue Growth
16.83%
EPS Growth
-494.61%
Country
US
Employees
625
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenid...

Gyre Therapeutics Financial Statement Overview

Summary

Financials are mixed: very strong gross margin (~94%) and a strong, low-leverage balance sheet (debt-to-equity ~0.03) support stability, but profitability has deteriorated to a TTM net loss (net margin ~-15%) and operating cash flow is slightly negative (~-$2.4M) despite improved, positive TTM free cash flow (~$4.3M).

Income Statement

58Neutral

Balance Sheet

82Very Positive

Cash Flow

46Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue119.38M116.59M105.76M113.45M102.29M7.34M
Gross Profit112.58M111.17M101.87M108.81M97.50M-332.00K
EBITDA-12.61M16.92M17.82M20.33M10.54M-87.64M
Net Income-17.33M5.03M12.09M-92.93M2.30M-87.93M
Balance Sheet
Total Assets199.25M166.13M125.41M116.54M84.75M55.66M
Cash, Cash Equivalents and Short-Term Investments74.80M52.42M26.67M33.51M25.18M46.85M
Total Debt3.42M939.00K1.60M409.00K613.00K2.38M
Total Liabilities34.34M23.85M27.00M102.59M12.54M14.57M
Stockholders Equity130.36M106.03M63.32M-15.83M42.52M41.09M
Cash Flow
Free Cash Flow-16.79M-180.00K-6.77M17.31M5.68M-84.59M
Operating Cash Flow-14.50M1.01M-3.64M25.89M10.68M-83.75M
Investing Cash Flow7.30M-474.00K-19.88M-19.76M-13.81M48.19M
Financing Cash Flow696.00K24.38M2.10M2.50M049.55M

Gyre Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price4.01

Price Trends

50DMA6.55Negative
100DMA6.49Negative
200DMA6.92Negative

Market Momentum

MACD-0.61Positive
RSI27.18Positive
STOCH4.54Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Negative. The current price of 4.01 is below the 20-day moving average (MA) of 5.89, below the 50-day MA of 6.55, and below the 200-day MA of 6.92, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 27.18 is Positive, neither overbought nor oversold. The STOCH value of 4.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GYRE.

Gyre Therapeutics Risk Analysis

Gyre Therapeutics disclosed 98 risk factors in its most recent earnings report. Gyre Therapeutics reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.Our common stock is thinly traded and our outstanding shares are concentrated among a small number of holders. Sales of a substantial number of shares of our common stock, including in connection with the expiration of contractual lock-up agreements or any foreclosure upon shares pledged by our controlling stockholder, or the perception that such sales could occur, could cause the market price of our common stock to decline significantly.Q2, 2026

Gyre Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GYRE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GYREGYRE55Neutral$470.79M-14.38-15.77%―16.83%-494.61%
SGMTSGMT53Neutral$702.71M-7.13-31.96%――30.54%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IVAIVA46Neutral$950.19M-6.34-1625.48%―-99.61%66.37%
GALTGALT44Neutral$349.95M-6.9921.48%――33.25%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GYREGALTIVASGMTAVLNVCREDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GYRE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GYREGyre Therapeutics Inc4.01-3.20-44.38%
GALTGalectin Therapeutics (GALT)2.98-2.22-42.60%
IVAInventiva SA ADR3.63-0.38-9.48%
SGMTSagimet Biosciences, Inc. Class A9.121.6021.28%
AVLNAvalyn Pharma Inc26.67-2.82-9.56%
VCREVicore Pharma Holding AB Sponsored ADR10.01-3.45-25.65%

Gyre Therapeutics Corporate Events

Business Operations and StrategyExecutive/Board Changes

Gyre Therapeutics Secures CEO and CFO with New Contracts

Positive
Oct 22, 2026

On October 16, 2026, Gyre Therapeutics entered into new employment agreements with Chief Executive Officer Ying Luo, Ph.D., and Chief Financial Officer Thomas Eastling, formalizing their continued service and compensation packages. The contracts set...

Business Operations and StrategyFinancial Disclosures

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

Positive
Sep 1, 2026

On September 1, 2026, Gyre Therapeutics made an updated corporate presentation available, highlighting a global, capital‑efficient development model that uses revenue from its established China commercial operations to help fund early-stage res...

Business Operations and Strategy

Gyre Therapeutics unveils capital-efficient global development strategy

Positive
Aug 26, 2026

On August 26, 2026, Gyre Therapeutics released an updated corporate presentation detailing a capital-efficient global development strategy that uses revenue from its established China operations, including the market-leading IPF drug ETUARY, to help...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026